h5-index is the h-index for articles published in the last 5 complete years. It is the largest number h such that h articles published in 2014-2018 have at least h citations each.hide
h5-median for a publication is the median number of citations for the articles that make up its h5-index.hide
Title / AuthorCited byYear
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The Lancet Oncology 16 (4), 375-384
14992015
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The Lancet Oncology 15 (12), e538-e548
14892014
Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study
R De Angelis, M Sant, MP Coleman, S Francisci, P Baili, D Pierannunzio, ...
The Lancet Oncology 15 (1), 23-34
13442014
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ...
The Lancet Oncology 15 (2), 213-222
12322014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
H Wilke, K Muro, E Van Cutsem, SC Oh, G Bodoky, Y Shimada, ...
The Lancet Oncology 15 (11), 1224-1235
10822014
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The Lancet Oncology 16 (1), 25-35
10732015
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
V Heinemann, LF von Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, ...
The Lancet Oncology 15 (10), 1065-1075
10502014
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ...
The Lancet Oncology 16 (3), 257-265
9452015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The Lancet Oncology 16 (8), 908-918
9302015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The Lancet Oncology 16 (2), 141-151
9242015
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The Lancet Oncology 15 (8), 852-861
8932014
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
JD Bradley, R Paulus, R Komaki, G Masters, G Blumenschein, S Schild, ...
The Lancet Oncology 16 (2), 187-199
8622015
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie, P Balter, HJM Groen, ...
The Lancet Oncology 16 (6), 630-637
7992015
Breast cancer in China
L Fan, K Strasser-Weippl, JJ Li, J St Louis, DM Finkelstein, KD Yu, ...
The Lancet Oncology 15 (7), e279-e289
7612014
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ...
The Lancet Oncology 15 (3), 323-332
7522014
Carcinogenicity of consumption of red and processed meat
V Bouvard, D Loomis, KZ Guyton, Y Grosse, F El Ghissassi, ...
The Lancet Oncology 16 (16), 1599-1600
7432015
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM van den Eertwegh, ...
The Lancet Oncology 15 (7), 700-712
7352014
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
J Shapiro, JJB van Lanschot, MCCM Hulshof, P van Hagen, ...
The Lancet Oncology 16 (9), 1090-1098
7202015
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
M Donker, G van Tienhoven, ME Straver, P Meijnen, CJH van de Velde, ...
The Lancet Oncology 15 (12), 1303-1310
6692014
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160
6632015
1 - 20
Dates and citation counts are estimated and are determined automatically by a computer program.